Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT05886205

Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy

Exploratory Clinical Study on Induced Pluripotent Stem Cell Derived Exosomes (GD-iEXo-002) Nasal Drops for the Treatment of Refractory Focal Epilepsy

Sponsor: Guidon Pharmaceutics Ltd.

Conditions Refractory Focal Epilepsy

Interventions iPSC-Exos

Updated 4 times since 2023 Last updated: Jun 5, 2023 Started: Jun 5, 2023 Primary completion: Jun 13, 2025 Completion: Nov 13, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Refractory Focal Epilepsy, this trial is ongoing. The trial is conducted by Guidon Pharmaceutics Ltd. and has accumulated 4 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Unknown EARLY_PHASE1

Status: Recruiting → Unknown
Sep 2024 — Dec 2025 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Jul 2023 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guidon Pharmaceutics Ltd.
Peking Union Medical College Hospital

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China